\n<\/p>\n
\n \n \n Add topic to email alerts \n <\/span> \n <\/p>\n\n\n \n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nCOPENHAGEN, Denmark \u2014In this Healio video, Balazs Halmos, MD, MS, <\/b>discusses results from the TOP trial, presented at European Lung Cancer Congress.<\/p>\nThe phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR<\/i> and TP53 mutations.<\/p>\n\u201cChemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,\u201d Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.<\/p>\n
\n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nCOPENHAGEN, Denmark \u2014In this Healio video, Balazs Halmos, MD, MS, <\/b>discusses results from the TOP trial, presented at European Lung Cancer Congress.<\/p>\nThe phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR<\/i> and TP53 mutations.<\/p>\n\u201cChemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,\u201d Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.<\/p>\n
“ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nCOPENHAGEN, Denmark \u2014In this Healio video, Balazs Halmos, MD, MS, <\/b>discusses results from the TOP trial, presented at European Lung Cancer Congress.<\/p>\nThe phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR<\/i> and TP53 mutations.<\/p>\n\u201cChemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,\u201d Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.<\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nCOPENHAGEN, Denmark \u2014In this Healio video, Balazs Halmos, MD, MS, <\/b>discusses results from the TOP trial, presented at European Lung Cancer Congress.<\/p>\nThe phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR<\/i> and TP53 mutations.<\/p>\n\u201cChemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,\u201d Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.<\/p>\n
COPENHAGEN, Denmark \u2014In this Healio video, Balazs Halmos, MD, MS, <\/b>discusses results from the TOP trial, presented at European Lung Cancer Congress.<\/p>\n
The phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR<\/i> and TP53 mutations.<\/p>\n
\u201cChemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,\u201d Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.<\/p>\n
![\"hemonc](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hot.svg?la=en&h=24&w=141&hash=2F86D471C8514C0E334E329AA799E8B4\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n